Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
- Written by PR Newswire
- Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau
- No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo
- Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4...














